GILD — GILEAD SCIENCES, INC.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 882095 ·
Last close
$170.26
Market Cap
$211.18B
52W High
$176.58
52W Low
$114.81
ADV30
6,357,713
Next earnings
2026-10-29
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | — | — | — | — | — | — | — |
| Jun 2026 | 7,803,000,000 | 6,224,000,000 | 2,539,000,000 | -10,496,000,000 | 49,362,000,000 | 3,179,000,000 | 37,618,000,000 |
| Mar 2026 | 6,960,000,000 | 5,515,000,000 | 2,692,000,000 | 2,021,000,000 | 56,278,000,000 | 7,628,000,000 | 32,847,000,000 |
| Dec 2025 | 7,924,000,000 | 6,300,000,000 | 2,988,000,000 | 2,183,000,000 | 59,023,000,000 | 7,564,000,000 | 36,405,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$13,550,000,000
Investing CF
$-10,839,000,000
Financing CF
$-4,647,000,000
CapEx
$-609,000,000
Dividends Paid
$-4,068,000,000
Buybacks
$-1,439,000,000
EPS Diluted TTM
$-3.16
As of
2026-11-01
Balance + Analyst (yfinance extras)
Retained Earnings
$2,200,000,000
Inventory
$1,953,000,000
Receivables
$5,055,000,000
ST Investments
$0
EBIT TTM
$-957,000,000
Pretax Income TTM
$-1,955,000,000
Interest Exp TTM
$998,000,000
Analysts
26
Yahoo Snapshot (yfinance, live)
Total Revenue
$30,987,999,232
EBITDA
$15,351,000,064
Free Cash Flow
$12,642,374,656
Enterprise Value
$231,827,881,984
Total Cash
$6,437,000,192
Total Debt
$26,450,999,296
Shares Out
1,240,338,614
Trailing EPS
$-3.13
Book Value
$10.44
ROE
-22.4%
ROA
14.3%
Div Yield
1.92%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 29,442,000,000 | 11,701,000,000 | 8,510,000,000 | 59,023,000,000 | 36,405,000,000 | 22,702,000,000 | 10,019,000,000 |
| Dec 2024 | 28,754,000,000 | 10,596,000,000 | 480,000,000 | 58,995,000,000 | 39,749,000,000 | 19,330,000,000 | 10,828,000,000 |
| Dec 2023 | 27,116,000,000 | 8,838,000,000 | 5,665,000,000 | 62,125,000,000 | 39,376,000,000 | 22,833,000,000 | 8,006,000,000 |
| Dec 2022 | 27,281,000,000 | 10,974,000,000 | 4,592,000,000 | 63,171,000,000 | 41,962,000,000 | 21,240,000,000 | 9,072,000,000 |
TTM Snapshot
Revenues TTM
$30,457,000,000
NetIncome TTM
$-3,240,000,000
OpCashFlow TTM
—
Assets (Latest)
$49,362,000,000
Forward EPS
$10.06
Max Pain — expiry 2026-12-18
max pain strike: $90.00 · spot: $168.98 · call oi: 25 · put oi: 1,382
Expected Move to 2026-12-18:
±$12.58
(7.44%) —
implied range
$156.40 –
$181.56
· ATM straddle on $170.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AMGN | AMGEN INC | $247.70B | $457.93 | — |
| MRNA | Moderna, Inc. | $82.56B | $206.80 | — |
| ARGX | ARGENX SE | $58.92B | $947.52 | — |
| BIIB | BIOGEN INC. | $37.07B | $250.79 | — |
| RVMD | Revolution Medicines, Inc. | $35.19B | $162.69 | — |
News headlines (Yahoo Finance, 1h cache)
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
2026-11-18 13:00 · Yahoo
iShares Biotechnology ETF (IBB) Buys $16.2 Million More Gilead on Nov. 16
2026-11-18 11:05 · Yahoo
Gilead Sciences Maps Growth Beyond BIKTARVY With HIV, Cancer and Inflammation Drugs
2026-11-17 16:16 · Yahoo
Suffolk Celebrates Completion of Gilead Sciences Research Center With Ribbon Cutting
2026-11-17 16:00 · Yahoo
Biotechnology Market Companies 2027 Analysis: Amgen, Gilead, Regeneron, Vertex and Moderna Post Strong 2026 Results as Billion-Dollar Deals Reshape a Market Headed for USD 6.34 Trillion by 2035
2026-11-17 15:00 · Yahoo
Allogeneic Cell Therapy - Global Strategic Business Report 2026: Capitalize on 27.7% CAGR to Capture $2.4B by 2032 with Allogene, Gilead Sciences, Atara and Nkarta
2026-11-17 14:53 · Yahoo
Gilead Sciences Bets on HIV Prevention Growth Despite $1.5 Billion Biktarvy Headwind
2026-11-17 13:12 · Yahoo
What iShares Biotechnology ETF (IBB) Bought: Gilead Leads on Nov. 13
2026-11-17 11:05 · Yahoo
Gilead Sciences (GILD) Grants Royalty Free Ebola Drug Licenses For Lower Income Countries
2026-11-17 01:06 · Yahoo
These 3 Dividend Stocks Have Crushed the Market This Year. Here’s Why They Are Still Buys
2026-11-17 00:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.